Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Malou Cp Kuppen; Hans M Westgeest; Maarten J van der Doelen; Alphonsus Jm van den Eertwegh; Jules Llm Coenen; Katja Kh Aben; Alphons Cm van den Bergh; Andries M Bergman; Joan van den Bosch; Filiz Celik; Mathijs P Hendriks; Jules Lavalaye; Saskia van der Meer; Marco B Polee; Diederik M Somford; Inge M van Oort; Carin A Uyl-de Groot; Winald R Gerritsen

doi:https://doi.org/10.2217/fon-2020-0039

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Malou Cp Kuppen, Hans M Westgeest, Maarten J van der Doelen, Alphonsus Jm van den Eertwegh, Jules Llm Coenen, Katja Kh Aben, Alphons Cm van den Bergh, Andries M Bergman, Joan van den Bosch, Filiz Celik, Mathijs P Hendriks, Jules Lavalaye, Saskia van der Meer, Marco B Polee, Diederik M Somford, Inge M van Oort, Carin A Uyl-de Groot, Winald R Gerritsen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

Original language	English
Pages (from-to)	1371-1384
Number of pages	14
Journal	Future oncology
Volume	16
Issue number	19
DOIs	https://doi.org/10.2217/fon-2020-0039
Publication status	Published - Jul 2020

Keywords

metastatic castration-resistant prostate cancer
radium-223
real-world outcomes
sequencing
skeletal-related events
survival

Access to Document

https://doi.org/10.2217/fon-2020-0039

Cite this

Kuppen, M. C., Westgeest, H. M., van der Doelen, M. J., van den Eertwegh, A. J., Coenen, J. L., Aben, K. K., van den Bergh, A. C., Bergman, A. M., den Bosch, J. V., Celik, F., Hendriks, M. P., Lavalaye, J., der Meer, S. V., Polee, M. B., Somford, D. M., van Oort, I. M., Uyl-de Groot, C. A., & Gerritsen, W. R. (2020). Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future oncology, 16(19), 1371-1384. https://doi.org/10.2217/fon-2020-0039

@article{072f23e689914c39b11bb0626769d936,

title = "Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer",

abstract = "Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.",

keywords = "metastatic castration-resistant prostate cancer, radium-223, real-world outcomes, sequencing, skeletal-related events, survival",

author = "Kuppen, {Malou Cp} and Westgeest, {Hans M} and {van der Doelen}, {Maarten J} and {van den Eertwegh}, {Alphonsus Jm} and Coenen, {Jules Llm} and Aben, {Katja Kh} and {van den Bergh}, {Alphons Cm} and Bergman, {Andries M} and {den Bosch}, {Joan van} and Filiz Celik and Hendriks, {Mathijs P} and Jules Lavalaye and {der Meer}, {Saskia van} and Polee, {Marco B} and Somford, {Diederik M} and {van Oort}, {Inge M} and {Uyl-de Groot}, {Carin A} and Gerritsen, {Winald R}",

year = "2020",

month = jul,

doi = "https://doi.org/10.2217/fon-2020-0039",

language = "English",

volume = "16",

pages = "1371--1384",

journal = "Future oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "19",

}

Kuppen, MC, Westgeest, HM, van der Doelen, MJ, van den Eertwegh, AJ, Coenen, JL, Aben, KK, van den Bergh, AC, Bergman, AM, den Bosch, JV, Celik, F, Hendriks, MP, Lavalaye, J, der Meer, SV, Polee, MB, Somford, DM, van Oort, IM, Uyl-de Groot, CA & Gerritsen, WR 2020, 'Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer', Future oncology, vol. 16, no. 19, pp. 1371-1384. https://doi.org/10.2217/fon-2020-0039

TY - JOUR

T1 - Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

AU - Kuppen, Malou Cp

AU - Westgeest, Hans M

AU - van der Doelen, Maarten J

AU - van den Eertwegh, Alphonsus Jm

AU - Coenen, Jules Llm

AU - Aben, Katja Kh

AU - van den Bergh, Alphons Cm

AU - Bergman, Andries M

AU - den Bosch, Joan van

AU - Celik, Filiz

AU - Hendriks, Mathijs P

AU - Lavalaye, Jules

AU - der Meer, Saskia van

AU - Polee, Marco B

AU - Somford, Diederik M

AU - van Oort, Inge M

AU - Uyl-de Groot, Carin A

AU - Gerritsen, Winald R

PY - 2020/7

Y1 - 2020/7

N2 - Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

AB - Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

KW - metastatic castration-resistant prostate cancer

KW - radium-223

KW - real-world outcomes

KW - sequencing

KW - skeletal-related events

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85087110450&partnerID=8YFLogxK

U2 - https://doi.org/10.2217/fon-2020-0039

DO - https://doi.org/10.2217/fon-2020-0039

M3 - Article

C2 - 32469606

SN - 1479-6694

VL - 16

SP - 1371

EP - 1384

JO - Future oncology

JF - Future oncology

IS - 19

ER -

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this